Capital Analysts LLC Increases Holdings in Abbott Laboratories $ABT

Key Points

• Capital Analysts LLC increased its Abbott Laboratories stake by 9.3% in the second quarter, bringing its holdings to 126,703 shares valued at approximately $11.5 million. Institutional investors collectively own 75.18% of ABT.
• Abbott reported quarterly earnings of $1.31 per share and revenue of $12.59 billion, exceeding analyst expectations, while revenue rose 13% year over year. The company issued fiscal 2026 EPS guidance of $5.45–$5.60.
• Abbott pays a quarterly dividend of $0.63 per share, equivalent to a 2.4% annual yield. Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $119.50.

Capital Analysts LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 9.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,703 shares of the healthcare product maker's stock after purchasing an additional 10,819 shares during the period. Capital Analysts LLC's holdings in Abbott Laboratories were worth $11,497,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the business. Brighton Jones LLC boosted its stake in shares of Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in Abbott Laboratories by 3.5% in the second quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker's stock worth $648,000 after buying an additional 162 shares during the period. United Bank boosted its position in Abbott Laboratories by 7.4% during the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker's stock valued at $3,945,000 after acquiring an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC boosted its position in Abbott Laboratories by 13.6% during the 2nd quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker's stock valued at $1,618,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Canada Pension Plan Investment Board grew its holdings in shares of Abbott Laboratories by 25.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker's stock worth $195,267,000 after acquiring an additional 292,547 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Down 2.5%

NYSE ABT opened at $105.66 on Wednesday. The stock has a 50 day moving average price of $105.04 and a 200-day moving average price of $99.95. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. The company has a market capitalization of $182.82 billion, a P/E ratio of 34.19, a P/E/G ratio of 2.01 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. During the same quarter last year, the firm earned $1.26 EPS. The firm's revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. Abbott Laboratories's payout ratio is 81.55%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Wolfe Research raised shares of Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price on the stock in a research report on Thursday, August 13th. Citigroup lifted their target price on shares of Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 17th. Wells Fargo & Company raised their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the company an "overweight" rating in a research report on Friday, July 17th. TD Cowen reiterated a "buy" rating and issued a $135.00 price target on shares of Abbott Laboratories in a research note on Tuesday. Finally, Bank of America dropped their price objective on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of "Moderate Buy" and an average price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories NYSE: ABT is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company's medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.